DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). At least it is an IPO in the United States. This is not a typical IPO that we are used to seeing because it is already listed and traded on the Euronext Paris under the symbol DBV. The company plans to list its depository shares on the Nasdaq Global Market under the proposed symbol DBVT.

The company is planning to register 3 million shares with a proposed maximum aggregate price of $32.02 per share. The offering can potentially raise up to $96.06 million. The underwriters for this offering will be Citigroup, Bryan Garnier & Co., Trout Capital and Leerink partners.

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on the field of immunotherapy, specifically its development of Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, the proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. This is being developed to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such an anaphylactic shock.

ALSO READ: Top IPO Stocks From This Year to Be Added to the Russell 2000

The lead product candidate, Viaskin Peanut, has obtained Fast Track designation from the U.S. FDA. In September 2014, topline results were announced for VIPES (Viaskin Peanut’s Efficacy and Safety), Phase 2b clinical trial of Viaskin Peanut in peanut allergic patients. Pending consultation with the FDA, the Phase 3 clinical trial is expected to take place in the first quarter of 2016.

DBV Technologies has further used its Viaskin technology platform to advance other innovative product development programs to address additional opportunities in immunology. It is also exploring earlier stage opportunities in respiratory syncytial virus vaccine, refractory hemophilia A, Crohn’s disease and type I diabetes.

The company plans to use the proceeds from this offering to advance the development of its Viaskin line, as well as fund its earlier stage development activities. The remainder will be used for building out the clinical and commercial infrastructure in the U.S. and supporting global growth.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.